靶点- |
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT - THE TREATMENT OF ADVANCED PROSTATE CANCER USING DISABLED CANCER CELLS AS VACCINES
A Phase I/II Trial of an Allogeneic Cell Based Vaccine and an Anti-Idiotypic Antibody Vaccine Approach for Metastatic Adenocarcinoma of the Colon or Rectum
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines made from cancer cells may make the body build an immune response to kill colorectal tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy and/or vaccine therapy in treating patients who have locally advanced or metastatic colorectal cancer.
100 项与 Onyvax Ltd. 相关的临床结果
0 项与 Onyvax Ltd. 相关的专利(医药)
100 项与 Onyvax Ltd. 相关的药物交易
100 项与 Onyvax Ltd. 相关的转化医学